04:28 AM EDT, 08/05/2025 (MT Newswires) -- Bristol-Myers Squibb ( BMY ) said late Monday the US Food and Drug Administration has accepted and granted priority review to its marketing application for its experimental cancer drug, Breyanzi.

The company said the health agency is expected to decide on Dec. 5 based on the primary analysis of the phase 2 trial.

Breyanzi is being developed by the company to treat adults with relapsed or refractory marginal zone lymphoma, who have received at least two prior lines of systemic therapy, the drugmaker said.